Early animal and lab research suggests that tiny folate-coated particles carrying the antiviral drug ganciclovir may keep the medicine in the eye longer. In rats, the particles raised drug levels in the eye’s vitreous fluid and caused no harmful eye side effects. According to research reviewed by Gram, human testing is still needed.
Herpes simplex virus can cause a serious eye infection called retinitis, and it is often treated with injections directly into the eye. Frequent injections can cause complications, so scientists tested a different approach. They packed the antiviral drug ganciclovir into tiny particles about 195 nanometers wide, made from chitosan (a substance found in crab and shrimp shells) and coated with folate, a B vitamin. In lab tests, the particles helped cells absorb more of the drug. In rats, they produced higher drug levels in the eye and a longer half-life than the plain drug solution, with no harmful eye side effects. According to research reviewed by Gram, these results are promising, but the work was done in lab dishes and animals, so it is too early to know whether it will help people.
Key Statistics
A 2026 study published in the European Journal of Pharmaceutics and Biopharmaceutics found that folate-chitosan nanoparticles, about 195 nanometers wide, helped rat eyes keep the antiviral drug ganciclovir for a longer time than the plain drug solution.
In a 2026 laboratory study, folate-chitosan particles containing ganciclovir had a 50% inhibitory concentration of 11.75 micrograms per milliliter against herpes simplex virus type 1, while only about 21% of the drug was successfully packed into the particles.
A 2026 study in rats found that injecting folate-chitosan nanoparticles into the eye did not cause harmful side effects, according to the researchers, though the exact number of animals was not specified.
The Quick Take
- What they studied: Could tiny particles carrying an antiviral eye medicine deliver it more effectively, so that fewer injections into the eye might be needed?
- Who participated: The study used lab-grown human eye cells (ARPE-19 cells) and laboratory rats. The exact number of rats was not specified in the study summary.
- Key finding: The particles helped cells absorb more of the drug and kept it in the rats’ eyes longer than the plain drug solution. The particles were about 195 nanometers wide, and only about 21% of the drug was successfully packed inside them.
- What it means for you: This is early research and does not change current treatment. People with eye infections should follow their doctor’s advice. The approach may someday offer a gentler option, but human testing is still needed.
The Research Details
The researchers first built the particles. They attached folate to chitosan, a natural material, using a chemical reaction. Then they mixed this material with the antiviral drug ganciclovir in a way that causes tiny droplets to form, a process called ionic gelation. This produced particles that carried the drug.
Next, they tested the particles in three ways. In the lab, they measured how much drug human eye cells absorbed and how well the particles stopped the herpes virus from spreading. They then injected the particles into the eyes of rats and measured how long the drug stayed in the eye’s vitreous fluid, the clear gel that fills the back of the eye. They compared these results with the plain drug solution. Finally, they checked the rats’ eyes for signs of harm.
This type of study is an early step in drug development. It shows whether an idea is worth testing further before any human trials begin.
Testing in cells and animals comes before human studies because it can reveal whether a new delivery method works and appears safe. Measuring drug levels over time in the eye shows whether the particles actually keep the medicine present longer. Checking for eye damage is important because any new eye treatment must be safe before it can be considered for people.
The study followed a clear, step-by-step process and measured several outcomes, which strengthens its findings. However, it was carried out in lab cells and rats, and results in animals do not always match results in people. The study summary also does not specify the number of animals used, which makes it harder to judge how strong the results are. The particles captured only about 21% of the drug, which is a limitation to address in future work. The research was published in a respected pharmaceutical science journal, which means it went through expert review.
What the Results Show
The particles were about 195 nanometers wide, which is far smaller than the width of a human hair. They carried a positive electrical charge, which may help them interact with cells. Only about 21% of the drug was successfully trapped inside the particles, so most of the drug was not packed in. This is an important limitation, though the researchers still found clear benefits.
In lab tests on human eye cells, the particles helped cells take in significantly more of the drug than the drug alone. The particles also stopped the herpes virus from spreading in lab dishes. The amount needed to block half of the virus, known as the IC50, was 11.75 micrograms per milliliter, plus or minus 1.82.
In rats, the particles kept the drug in the vitreous fluid for longer. The study reported a higher AUC, which is a measure of total drug exposure over time, and a longer half-life, which means the drug was cleared from the eye more slowly. These results suggest the particles may reduce how often the medicine would need to be given.
The researchers also found that injecting the particles into the rats’ eyes did not cause harmful side effects. This is an encouraging safety signal, though more detailed safety testing would be needed before any human use.
The particle approach may be useful because injections into the eye carry risks, such as infection, bleeding, and increased eye pressure. A delivery method that keeps medicine in the eye longer could mean fewer injections over time. The safety result in rats is also significant, since safety is a key hurdle for any new eye treatment. The folate coating may help the particles reach eye cells, although this was not separately confirmed in the summary.
Injected ganciclovir is already an accepted treatment for this type of eye infection, so the research is building on established medicine. Other researchers have also explored nanoparticles and biodegradable materials to deliver eye medicines more slowly. This study adds to that work by combining a targeting coating (folate) with a natural material (chitosan) and showing longer drug presence in the eye. Its results fit the broader trend of using tiny carriers to improve how eye drugs work, though it remains an early-stage example.
The most important limitation is that the study was done in cells and rats, not people. Animal eyes differ from human eyes, so results may not carry over. The particles trapped only about 21% of the drug, meaning much of the medicine was not delivered through the particles. The study summary does not state how many animals were used or how long the follow-up lasted, which makes it harder to judge reliability. Long-term safety, the best dose, and how the particles behave over many months are also unknown. Human clinical trials would be needed to answer these questions.
The Bottom Line
Based on current evidence, this approach is promising but still experimental. Confidence that the particles work in people is low at this stage because the evidence comes only from lab cells and rats. Confidence that the particles are a useful research direction is moderate, since the lab and animal results were encouraging. People with herpes eye infections should continue to follow their doctor’s current treatment plan.
Eye doctors, pharmaceutical researchers, and drug developers may find this study useful for guiding future work. Patients with herpes-related eye infections may be interested in the research, but should not change treatment based on it. People without eye infections do not need to act on these findings.
Drug delivery research usually takes many years before reaching patients. Typically, a new approach must pass further animal testing, safety trials in people, and effectiveness trials before it could be approved. Patients should not expect this specific treatment to become available for several years at the earliest, and only if future studies succeed.
Frequently Asked Questions
Can nanoparticles help treat herpes eye infections?
Early lab and rat research suggests they may. Folate-chitosan nanoparticles carrying ganciclovir kept the drug in rat eyes longer than the plain solution and showed no harmful eye side effects. Human studies are still needed before any clinical use.
What is ganciclovir used for in the eye?
Ganciclovir is an antiviral medicine used to treat herpes simplex virus eye infections, such as retinitis. It is currently given as an injection directly into the eye. Frequent injections can cause complications, which is why researchers are exploring gentler delivery methods.
Are eye injections for herpes infections risky?
Repeated eye injections can cause complications, according to the research summary. Doctors weigh these risks against the benefits of treatment. Anyone with an eye infection should follow their eye doctor’s guidance rather than change treatment based on early research findings.
How small are nanoparticles used for eye drug delivery?
The folate-chitosan particles in this study were about 195 nanometers wide. That is far smaller than the width of a human hair. Their small size and positive electrical charge may help them interact with eye cells, though human results are not yet available.
Want to Apply This Research?
- If you have a history of eye infections, track the date of each eye symptom, such as redness, pain, light sensitivity, or blurred vision, along with the date of any doctor visit or treatment. Record the number of eye injections or medication doses you receive each month. This creates a clear record to discuss with your eye doctor.
- Set a reminder for scheduled eye appointments and medication doses so you do not miss important treatment. Use the app to note any new symptoms right away, and share this log with your doctor. Avoid self-treating or changing medication based on news about early research.
- Over the long term, keep a simple monthly log of eye symptoms, treatments, and doctor visits. Review the log every few months with your eye care team to spot patterns. If new treatment options become available in the future, use this record to help decide whether they suit your needs.
This article summarizes early-stage laboratory and animal research and is for general education only. The findings have not been tested in humans and do not establish a treatment. Herpes eye infections can cause serious vision loss, so anyone with symptoms should see an eye doctor promptly. Do not change or stop any prescribed treatment based on this research. Consult your healthcare provider before making any decisions about your eye health.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.